STOCKHOLM, Sweden, Sept. 21, 2004 (PRIMEZONE) -- Elekta:
- Profit after taxes rose with 32 percent to SEK 54 M (41). Earnings per share before dilution increased to SEK 1.74 (1.26) and after dilution to SEK 1.73 (1.24).
- Operating profit increased by 42 percent to SEK 75 M (53) and the operating margin was 10 percent (9).
- Cash flow after investments was negative SEK 112 M (neg: 24) mainly as a result of increased tied up working capital.
- Order bookings amounted to SEK 688 M (835), a decline with 18 percent compared to the strong first quarter last year. At fixed exchange rates, the Group's order bookings declined 16 percent.
- Order backlog remains at a high level and was on July 31, 2004 at SEK 2,717 M, compared with SEK 2,728 M at April 30, 2004.
- Net sales rose 17 percent to SEK 717 M (615). At fixed exchange rates, net sales increased 18 percent.
For the full report, please see enclosed pdf file.
For further information, please contact:
Peter Ejemyr, Group VP Corporate Communications, Elekta AB (publ), Phone: +46 733 611 000, e-mail: peter.ejemyr@elekta.com
Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective, cost efficient and gentle to the patient.
For additional information about Elekta, please visit www.elekta.com
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/09/21/20040921BIT20880/wkr0001.pdf